Regeneron Pharmaceuticals, Inc. (REGN) Company Bio
Regeneron Pharmaceuticals is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, and atopic dermatitis. The company was founded in 1988 and is based in Tarrytown, New York.
REGN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Regeneron Pharmaceuticals Inc. To summarize, we found that Regeneron Pharmaceuticals Inc ranked in the 54th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 12.5% on a DCF basis. The most interesting components of our discounted cash flow analysis for Regeneron Pharmaceuticals Inc ended up being:
Interest coverage, a measure of earnings relative to interest payments, is 72.22 -- which is good for besting 94.36% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
The business' balance sheet suggests that 4% of the company's capital is sourced from debt; this is greater than only 15.58% of the free cash flow producing stocks we're observing.
REGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 44.27% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
FONR, CMD, DXCM, UNH, and FZMD can be thought of as valuation peers to REGN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Regeneron (REGN) reports that data from a late-stage trial evaluating its casirivimab and imdevimab antibody cocktail known as REGEN-COV indicates it is effective in preventing COVID-19 infection.Interim analysis on the first 400 patients randomized to receive the cocktail or a placebo showed those in the active arm had 100% prevention...
After strong performance in 2020, biopharma stocks are expected to continue their winning run in the new year. Among the companies in the space, analysts at BMO Capital Markets are particularly bullish on Regeneron Pharmaceuticals Inc (NASDAQ: REGN and Constellation Pharmaceuticals Inc (NASDAQ: CNST ). The Regeneron, Constellation Analysts: Analyst Matthew Luchini upgraded Regeneron from Neutral to Outperform and maintained the price target at $630. Analyst Do Kim upgraded Constellation shares from Market Perform to Outperform and increased the price target from $27 to $50. The Regeneron Thesis: The potential exists for continued strong performance from Regeneron's retinal disorder treatment Eylea, the dermatitis and asthma drug Dupixent and the advanced cutaneous squamous cell carcinom...
NEW YORK, Jan. 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIU, REGN, GE, MRK, and AAXN. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different…